What is HC Wainwright's Estimate for BDTX FY2026 Earnings?

Key Points

• HC Wainwright predicts Black Diamond Therapeutics will have an earnings per share of ($1.04) for FY2026, maintaining a "Buy" rating with a price target of $10.00.
• Black Diamond has received mixed ratings from analysts, with Wall Street Zen downgrading it to a "hold" while Raymond James upgraded it to "outperform" with a $11.00 target price.
• The stock has a market capitalization of $152.26 million and has traded between $1.20 and $6.75 over the past year, with institutional investors holding 95.47% of shares.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Black Diamond Therapeutics in a research report issued on Monday, August 11th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($1.04) per share for the year. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share.

A number of other research firms also recently issued reports on BDTX. Wall Street Zen downgraded shares of Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday. Raymond James Financial upgraded shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 target price on the stock in a research report on Tuesday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $12.40.

Black Diamond Therapeutics Price Performance

BDTX opened at $2.67 on Wednesday. The firm has a market capitalization of $152.26 million, a price-to-earnings ratio of 11.48 and a beta of 2.87. Black Diamond Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $6.75. The company's 50 day moving average price is $2.64 and its two-hundred day moving average price is $2.14.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.06.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP raised its holdings in shares of Black Diamond Therapeutics by 11.4% in the fourth quarter. Vestal Point Capital LP now owns 5,600,000 shares of the company's stock valued at $11,984,000 after purchasing an additional 571,500 shares during the last quarter. Tang Capital Management LLC grew its position in Black Diamond Therapeutics by 51.1% during the fourth quarter. Tang Capital Management LLC now owns 2,070,209 shares of the company's stock valued at $4,430,000 after buying an additional 700,000 shares during the period. Geode Capital Management LLC grew its position in Black Diamond Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 959,316 shares of the company's stock valued at $2,053,000 after buying an additional 14,439 shares during the period. Renaissance Technologies LLC grew its position in Black Diamond Therapeutics by 256.2% during the fourth quarter. Renaissance Technologies LLC now owns 904,000 shares of the company's stock valued at $1,935,000 after buying an additional 650,200 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Black Diamond Therapeutics by 158.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 661,436 shares of the company's stock valued at $1,416,000 after buying an additional 405,579 shares during the period. Institutional investors and hedge funds own 95.47% of the company's stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.